Ralph L. Kodell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ralph L. Kodell has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- James J. Chen
Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, United States of America
6 shared publications - Hongshik Ahn
Department of Applied Mathematics and Statistics , Stony Brook University , Stony Brook , New York , USA
5 shared publications - David W. Gaylor
National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas 72079
3 shared publications - Hojin Moon
Division of Biometry and Risk Assessment, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Drive, Jefferson, AR 72079, USA
2 shared publications James J. Chen
Division of Bioinformatics and Biostatistics , National Center for Toxicological Research , Jefferson , Arkansas , USA
2 shared publicationsBruce A. Pearce
1 shared publication
Latest Publications
- Open Access
- 27 March 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 121
Immune Function and Muscle Adaptations to Resistance exercise in Older Adults: Study Protocol for a Randomized Controlled Trial of a Nutritional Supplement
Immune function may influence the ability of older adults to maintain or improve muscle mass, strength, and function during aging. Thus, nutritional supplementation that supports the immune system could complement resistance exercise as an intervention for age-associated muscle loss. The current study will determine the relationship between immune function and exercise training outcomes for older adults who consume a nutritional supplement or placebo during resistance training and post-training follow-up. The supplement was chosen due to evidence suggesting its ingredients [arginine (Arg), glutamine (Gln), and β-hydroxy β-methylbutyrate (HMB)] can improve immune function, promote muscle growth, and counteract muscle loss. Veterans (age 60 to 80 yrs, N = 50) of the United States military will participate in a randomized double-blind placebo-controlled trial of consumption of a nutritional supplement or placebo during completion of three study objectives: 1) determine if 2 weeks of supplementation improve immune function measured as the response to vaccination and systemic and cellular responses to acute resistance exercise; 2) determine if supplementation during 36 sessions of resistance training boosts gains in muscle size, strength, and function; and 3) determine if continued supplementation for 26 weeks post-training promotes retention of training-induced gains in muscle size, strength, and function. Analyses of the results for these objectives will determine the relationship between immune function and the training outcomes. Participants will undergo nine blood draws and five muscle (vastus lateralis) biopsies so that the effects of the supplement on immune function and the systemic and cellular responses to exercise can be measured. Exercise has known effects on immune function. However, the study will attempt to modulate immune function using a nutritional supplement and determine the effects on training outcomes. The study will also examine post-training benefit retention, an important issue for older adults, usually omitted from exercise studies. The study will potentially advance our understanding of the mechanisms of muscle gain and loss in older adults, but more importantly, a nutritional intervention will be evaluated as a complement to exercise for supporting muscle health during aging. Clinicaltrials.gov identifier: NCT02261961 , registration date 10 June 2014, recruitment active.
- 27 March 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 121
Open AccessImmune Function and Muscle Adaptations to Resistance exercise in Older Adults: Study Protocol for a Randomized Controlled Trial of a Nutritional Supplement
Immune function may influence the ability of older adults to maintain or improve muscle mass, strength, and function during aging. Thus, nutritional supplementation that supports the immune system could complement resistance exercise as an intervention for age-associated muscle loss. The current study will determine the relationship between immune function and exercise training outcomes for older adults who consume a nutritional supplement or placebo during resistance training and post-training follow-up. The supplement was chosen due to evidence suggesting its ingredients [arginine (Arg), glutamine (Gln), and β-hydroxy β-methylbutyrate (HMB)] can improve immune function, promote muscle growth, and counteract muscle loss. Veterans (age 60 to 80 yrs, N = 50) of the United States military will participate in a randomized double-blind placebo-controlled trial of consumption of a nutritional supplement or placebo during completion of three study objectives: 1) determine if 2 weeks of supplementation improve immune function measured as the response to vaccination and systemic and cellular responses to acute resistance exercise; 2) determine if supplementation during 36 sessions of resistance training boosts gains in muscle size, strength, and function; and 3) determine if continued supplementation for 26 weeks post-training promotes retention of training-induced gains in muscle size, strength, and function. Analyses of the results for these objectives will determine the relationship between immune function and the training outcomes. Participants will undergo nine blood draws and five muscle (vastus lateralis) biopsies so that the effects of the supplement on immune function and the systemic and cellular responses to exercise can be measured. Exercise has known effects on immune function. However, the study will attempt to modulate immune function using a nutritional supplement and determine the effects on training outcomes. The study will also examine post-training benefit retention, an important issue for older adults, usually omitted from exercise studies. The study will potentially advance our understanding of the mechanisms of muscle gain and loss in older adults, but more importantly, a nutritional intervention will be evaluated as a complement to exercise for supporting muscle health during aging. Clinicaltrials.gov identifier: NCT02261961 , registration date 10 June 2014, recruitment active.
- 1 January 2013
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 23 (1) , 231-238
Quantitative Benefit-Risk Analysis for Evaluating Drug Therapies
Despite the fact that benefit–risk analysis is a necessary component of the review of new drugs for potential regulatory approval in the presence of known adverse side effects, and of the review of already-approved drugs for possible withdrawal from the market when unanticipated adverse events are discovered, formal quantitative tools for benefit–risk analysis are few. This paper proposes a quantitative method that utilizes receiver operating characteristic (ROC) curves to find an optimal dose of a drug that maximizes the differential between the benefit of the intended effect and the risk of adverse side effects, where costs associated with lack of benefit and risk can be incorporated. The method can be applied separately to subpopulations of different sensitivities and to different adverse events to give a full picture of the trade-offs between the benefit afforded by the drug and the risk it incurs, and potentially to allow the drug to be approved only selectively for specific subpopulations, or at different doses for different subpopulations.
- 1 January 2013
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 23 (1) , 231-238
Quantitative Benefit-Risk Analysis for Evaluating Drug Therapies
Despite the fact that benefit–risk analysis is a necessary component of the review of new drugs for potential regulatory approval in the presence of known adverse side effects, and of the review of already-approved drugs for possible withdrawal from the market when unanticipated adverse events are discovered, formal quantitative tools for benefit–risk analysis are few. This paper proposes a quantitative method that utilizes receiver operating characteristic (ROC) curves to find an optimal dose of a drug that maximizes the differential between the benefit of the intended effect and the risk of adverse side effects, where costs associated with lack of benefit and risk can be incorporated. The method can be applied separately to subpopulations of different sensitivities and to different adverse events to give a full picture of the trade-offs between the benefit afforded by the drug and the risk it incurs, and potentially to allow the drug to be approved only selectively for specific subpopulations, or at different doses for different subpopulations.
- Open Access
- 28 November 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 656
Estimating misclassification error: a closer look at cross-validation based methods
To estimate a classifier’s error in predicting future observations, bootstrap methods have been proposed as reduced-variation alternatives to traditional cross-validation (CV) methods based on sampling without replacement. Monte Carlo (MC) simulation studies aimed at estimating the true misclassification error conditional on the training set are commonly used to compare CV methods. We conducted an MC simulation study to compare a new method of bootstrap CV (BCV) to k-fold CV for estimating clasification error.
- 28 November 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 656
Open AccessEstimating misclassification error: a closer look at cross-validation based methods
To estimate a classifier’s error in predicting future observations, bootstrap methods have been proposed as reduced-variation alternatives to traditional cross-validation (CV) methods based on sampling without replacement. Monte Carlo (MC) simulation studies aimed at estimating the true misclassification error conditional on the training set are commonly used to compare CV methods. We conducted an MC simulation study to compare a new method of bootstrap CV (BCV) to k-fold CV for estimating clasification error.
- Open Access
- 23 July 2012
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 12 (1) , 102
Assessment of performance of survival prediction models for cancer prognosis
Cancer survival studies are commonly analyzed using survival-time prediction models for cancer prognosis. A number of different performance metrics are used to ascertain the concordance between the predicted risk score of each patient and the actual survival time, but these metrics can sometimes conflict. Alternatively, patients are sometimes divided into two classes according to a survival-time threshold, and binary classifiers are applied to predict each patient’s class. Although this approach has several drawbacks, it does provide natural performance metrics such as positive and negative predictive values to enable unambiguous assessments.
- 23 July 2012
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 12 (1) , 102
Open AccessAssessment of performance of survival prediction models for cancer prognosis
Cancer survival studies are commonly analyzed using survival-time prediction models for cancer prognosis. A number of different performance metrics are used to ascertain the concordance between the predicted risk score of each patient and the actual survival time, but these metrics can sometimes conflict. Alternatively, patients are sometimes divided into two classes according to a survival-time threshold, and binary classifiers are applied to predict each patient’s class. Although this approach has several drawbacks, it does provide natural performance metrics such as positive and negative predictive values to enable unambiguous assessments.
- 17 March 2010
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 66 (1) , 239-248
Determination of Sample Sizes for Demonstrating Efficacy of Radiation Countermeasures
Summary In response to the ever increasing threat of radiological and nuclear terrorism, active development of nontoxic new drugs and other countermeasures to protect against and/or mitigate adverse health effects of radiation is ongoing. Although the classical LD50 study used for many decades as a first step in preclinical toxicity testing of new drugs has been largely replaced by experiments that use fewer animals, the need to evaluate the radioprotective efficacy of new drugs necessitates the conduct of traditional LD50 comparative studies ( FDA, 2002 , Federal Register 67, 37988–37998). There is, however, no readily available method to determine the number of animals needed for establishing efficacy in these comparative potency studies. This article presents a sample‐size formula based on Student's t for comparative potency testing. It is motivated by the U.S. Food and Drug Administration's (FDA's) requirements for robust efficacy data in the testing of response modifiers in total body irradiation experiments where human studies are not ethical or feasible. Monte Carlo simulation demonstrated the formula's performance for Student's t, Wald, and likelihood ratio tests in both logistic and probit models. Importantly, the results showed clear potential for justifying the use of substantially fewer animals than are customarily used in these studies. The present article may thus initiate a dialogue among researchers who use animals for radioprotection survival studies, institutional animal care and use committees, and drug regulatory bodies to reach a consensus on the number of animals needed to achieve statistically robust results for demonstrating efficacy of radioprotective drugs.
- 17 March 2010
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 66 (1) , 239-248
Determination of Sample Sizes for Demonstrating Efficacy of Radiation Countermeasures
Summary In response to the ever increasing threat of radiological and nuclear terrorism, active development of nontoxic new drugs and other countermeasures to protect against and/or mitigate adverse health effects of radiation is ongoing. Although the classical LD50 study used for many decades as a first step in preclinical toxicity testing of new drugs has been largely replaced by experiments that use fewer animals, the need to evaluate the radioprotective efficacy of new drugs necessitates the conduct of traditional LD50 comparative studies ( FDA, 2002 , Federal Register 67, 37988–37998). There is, however, no readily available method to determine the number of animals needed for establishing efficacy in these comparative potency studies. This article presents a sample‐size formula based on Student's t for comparative potency testing. It is motivated by the U.S. Food and Drug Administration's (FDA's) requirements for robust efficacy data in the testing of response modifiers in total body irradiation experiments where human studies are not ethical or feasible. Monte Carlo simulation demonstrated the formula's performance for Student's t, Wald, and likelihood ratio tests in both logistic and probit models. Importantly, the results showed clear potential for justifying the use of substantially fewer animals than are customarily used in these studies. The present article may thus initiate a dialogue among researchers who use animals for radioprotection survival studies, institutional animal care and use committees, and drug regulatory bodies to reach a consensus on the number of animals needed to achieve statistically robust results for demonstrating efficacy of radioprotective drugs.
- 16 March 2010
- Published by Taylor & Francis in Personalized Medicine
- Vol. 7 (2) , 171-178
Is Premarket Identification of Hepatotoxic Drugs and Sensitive Patients Possible Based on High-Dimensional ‘Omic Data?
Idiosyncratic liver toxicity that may lead to post-marketing removal of approved drugs can potentially be explained by the existence of hidden, sensitive subpopulations that are not large enough to affect premarketing toxicity assessments. We consider whether molecular biomarkers of risk and response can be developed to identify sensitive individuals, using classification methods that allow for population heterogeneity represented by characteristics that may not be readily apparent or controlled. If so, drugs that may be hepatotoxic to only a relatively small subpopulation would not be mislabeled as hepatotoxic to the general population and could be prescribed selectively to achieve a maximum health benefit. We outline a possible strategy for identifying individuals who are highly susceptible to drug-related hepatotoxicity and point out the significant challenges.
- 16 March 2010
- Published by Taylor & Francis in Personalized Medicine
- Vol. 7 (2) , 171-178
Is Premarket Identification of Hepatotoxic Drugs and Sensitive Patients Possible Based on High-Dimensional ‘Omic Data?
Idiosyncratic liver toxicity that may lead to post-marketing removal of approved drugs can potentially be explained by the existence of hidden, sensitive subpopulations that are not large enough to affect premarketing toxicity assessments. We consider whether molecular biomarkers of risk and response can be developed to identify sensitive individuals, using classification methods that allow for population heterogeneity represented by characteristics that may not be readily apparent or controlled. If so, drugs that may be hepatotoxic to only a relatively small subpopulation would not be mislabeled as hepatotoxic to the general population and could be prescribed selectively to achieve a maximum health benefit. We outline a possible strategy for identifying individuals who are highly susceptible to drug-related hepatotoxicity and point out the significant challenges.
- 1 July 2009
- Published by Elsevier in Artificial Intelligence in Medicine
- Vol. 46 (3) , 267-276
A model-free ensemble method for class prediction with application to biomedical decision making
- 1 July 2009
- Published by Elsevier in Artificial Intelligence in Medicine
- Vol. 46 (3) , 267-276
A model-free ensemble method for class prediction with application to biomedical decision making
- 3 September 2008
- Published by Springer Nature in Environmental and Ecological Statistics
- Vol. 16 (1) , 3-12
Replace the NOAEL and LOAEL with the BMDL01 and BMDL10
- 3 September 2008
- Published by Springer Nature in Environmental and Ecological Statistics
- Vol. 16 (1) , 3-12
Replace the NOAEL and LOAEL with the BMDL01 and BMDL10
- 1 April 2007
- Published by Wiley in Risk Analysis
- Vol. 27 (2) , 433-437
On the Use of Hierarchical Probabilistic Models for Characterizing and Managing Uncertainty in Risk/Safety Assessment
A general probabilistically-based approach is proposed for both cancer and noncancer risk/safety assessments. The familiar framework of the original ADI/RfD formulation is used, substituting in the numerator a benchmark dose derived from a hierarchical pharmacokinetic/pharmacodynamic model and in the denominator a unitary uncertainty factor derived from a hierarchical animal/average human/sensitive human model. The empirical probability distributions of the numerator and denominator can be combined to produce an empirical human-equivalent distribution for an animal-derived benchmark dose in external-exposure units.
- 1 April 2007
- Published by Wiley in Risk Analysis
- Vol. 27 (2) , 433-437
On the Use of Hierarchical Probabilistic Models for Characterizing and Managing Uncertainty in Risk/Safety Assessment
A general probabilistically-based approach is proposed for both cancer and noncancer risk/safety assessments. The familiar framework of the original ADI/RfD formulation is used, substituting in the numerator a benchmark dose derived from a hierarchical pharmacokinetic/pharmacodynamic model and in the denominator a unitary uncertainty factor derived from a hierarchical animal/average human/sensitive human model. The empirical probability distributions of the numerator and denominator can be combined to produce an empirical human-equivalent distribution for an animal-derived benchmark dose in external-exposure units.
- 30 November 2004
- Published by Wiley in Statistics in Medicine
- Vol. 24 (8) , 1233-1244
An age-adjusted bootstrap-based Poly-k test
- 30 November 2004
- Published by Wiley in Statistics in Medicine
- Vol. 24 (8) , 1233-1244
An age-adjusted bootstrap-based Poly-k test